Centaurus Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Centaurus Financial’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,125	Closed	-$264K	–	2273
2018 Q2	$264K	Buy	+2,125	New	+$248K	0.04%	449

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Centaurus Financial's ALXN Position: Q3 2018 in Review

Centaurus Financial sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 2,125 shares — an estimated $264K sold.

Centaurus Financial first reported a position in ALXN in Q2 2018 and held it in 1 quarter. The position peaked at $264K in Q2 2018. 584 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

Centaurus Financial reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 2,125 Alexion Pharmaceuticals shares in Q3 2018, an estimated $264K.
Centaurus Financial first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Alexion Pharmaceuticals position peaked at $264K in Q2 2018.
584 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.